Eight patients with refractory acute myeloblastic leukemia (AML) and high-risk MDS received two doses of 2 × 108 WT-1-specific TCR-T cells, at a 4-week interval, associated with a mutated WT1 CYTWNQMNL peptide vaccine. The gene discussed is WT1; the disease is acute myeloid leukemia.